Characterization of antibody–drug conjugates by mass spectrometry: advances and future trends

Panowksi, 2014, Site-specific antibody drug conjugates for cancer therapy, mAbs, 6, 34, 10.4161/mabs.27022 Beck, 2010, Strategies and challenges for the next generation of therapeutic antibodies, Nat. Rev. Immunol., 10, 345, 10.1038/nri2747 Bross, 2001, Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia, Clin. Cancer Res., 7, 1490 Peters, 2015, Antibody–drug conjugates as novel anti-cancer chemotherapeutics, Biosci. Rep., 35, 10.1042/BSR20150089 Beck, 2010, The next generation of antibody–drug conjugates comes of age, Discov. Med., 10, 329 Panowski, 2013, Site-specific antibody drug conjugates for cancer therapy, mAbs, 6, 34, 10.4161/mabs.27022 Chari, 2008, Targeted cancer therapy: conferring specificity to cytotoxic drugs, Acc. Chem. Res., 41, 98, 10.1021/ar700108g Sun, 2005, Reduction–alkylation strategies for the modification of specific monoclonal antibody disulfides, Bioconj. Chem., 16, 1282, 10.1021/bc050201y Michaelsen, 1994, One disulfide bond in front of the second heavy chain constant region is necessary and sufficient for effector functions of human IgG3 without a genetic hinge, Proc. Natl. Acad. Sci. U. S. A., 91, 9243, 10.1073/pnas.91.20.9243 McCombs, 2015, Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry, AAPS J., 17, 339, 10.1208/s12248-014-9710-8 Okeley, 2013, Metabolic engineering of monoclonal antibody carbohydrates for antibody–drug conjugation, Bioconj. Chem., 24, 1650, 10.1021/bc4002695 Tumey, 2015, In vivo biotransformations of antibody–drug conjugates, Bioanalysis, 7, 1649, 10.4155/bio.15.84 Baron, 2015, Ado-trastuzumab emtansine (T-DM1): a novel antibody–drug conjugate for the treatment of HER2-positive metastatic breast cancer, J. Oncology Pharmacy Practice, 21, 132, 10.1177/1078155214527144 Doronina, 2003, Development of potent monoclonal antibody auristatin conjugates for cancer therapy, Nat. Biotech., 21, 778, 10.1038/nbt832 Dubowchik, 2002, Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity, Bioconj. Chem., 13, 855, 10.1021/bc025536j Woods, 2013, LC–MS characterization and purity assessment of a prototype bispecific antibody, MAbs, 5, 711, 10.4161/mabs.25488 Chen, 2011, Characterization of protein therapeutics by mass spectrometry: recent developments and future directions, Drug Discov. Today, 16, 58, 10.1016/j.drudis.2010.11.003 Gorovits, 2013, Bioanalysis of antibody–drug conjugates: American Association of Pharmaceutical Scientists Antibody–Drug Conjugate Working Group position paper, Bioanalysis, 5, 997, 10.4155/bio.13.38 Chen, 2013, Drug-to-antibody ratio (DAR) by UV/Vis spectroscopy, Methods Mol. Biol., 1045, 267, 10.1007/978-1-62703-541-5_16 Birdsall, 2015, A rapid on-line method for mass spectrometric confirmation of a cysteine-conjugated antibody–drug-conjugate structure using multidimensional chromatography, mAbs, 7, 1036, 10.1080/19420862.2015.1083665 Wakankar, 2011, Analytical methods for physicochemical characterization of antibody drug conjugates, mAbs, 3, 161, 10.4161/mabs.3.2.14960 Firth, 2015, A rapid approach for characterization of thiol-conjugated antibody–drug conjugates and calculation of drug–antibody ratio by liquid chromatography mass spectrometry, Anal. Biochem., 485, 34, 10.1016/j.ab.2015.06.001 Valliere-Douglass, 2015, Approaches to interchain cysteine-linked ADC characterization by mass spectrometry, Mol. Pharmaceut., 12, 1774, 10.1021/mp500614p Wagner-Rousset, 2013, Antibody–drug conjugate model fast characterization by LC–MS following IdeS proteolytic digestion, mAbs, 6, 173, 10.4161/mabs.26773 Hengel, 2014, Measurement of in vivo drug load distribution of cysteine-linked antibody–drug conjugates using microscale liquid chromatography mass spectrometry, Anal. Chem., 86, 3420, 10.1021/ac403860c Li, 2015, A size exclusion-reversed phase two dimensional-liquid chromatography methodology for stability and small molecule related species in antibody drug conjugates, J. Chromatogr. A, 1393, 81, 10.1016/j.chroma.2015.03.027 Valliere-Douglass, 2012, Native intact mass determination of antibodies conjugated with monomethyl auristatin E and F at interchain cysteine residues, Anal. Chem., 84, 2843, 10.1021/ac203346c Chen, 2013, Development of a native nanoelectrospray mass spectrometry method for determination of the drug-to-antibody ratio of antibody–drug conjugates, Anal. Chem., 85, 1699, 10.1021/ac302959p Xing, 2013, SCFFBXL3 ubiquitin ligase targets cryptochromes at their cofactor pocket, Nature, 496, 64, 10.1038/nature11964 Mehmood, 2014, Charge reduction stabilizes intact membrane protein complexes for mass spectrometry, J. Am. Chem. Soc., 136, 17010, 10.1021/ja510283g Politis, 2013, Integrative modelling coupled with ion mobility mass spectrometry reveals structural features of the clamp loader in complex with single-stranded DNA binding protein, J. Mol. Biol., 425, 4790, 10.1016/j.jmb.2013.04.006 Debaene, 2014, Innovative native MS methodologies for antibody drug conjugate characterization: high resolution native MS and IM–MS for average DAR and DAR distribution assessment, Anal. Chem., 86, 10674, 10.1021/ac502593n Huang, 2015, Utility of ion mobility mass spectrometry for drug-to-antibody ratio measurements in antibody–drug conjugates, J. Am. Soc. Mass Spectrom., 26, 1791, 10.1007/s13361-015-1203-1 Xu, 2011, Characterization of intact antibody–drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography–mass spectrometry, Anal. Biochem., 412, 56, 10.1016/j.ab.2011.01.004 Xu, 2013, Characterization of the drug-to-antibody ratio distribution for antibody–drug conjugates in plasma/serum, Bioanalysis, 5, 1057, 10.4155/bio.13.66 Janin-Bussat, 2015, Characterization of antibody drug conjugate positional isomers at cysteine residues by peptide mapping LC–MS analysis, J. Chromatogr. B, 981–982, 9, 10.1016/j.jchromb.2014.12.017 Dyachenko, 2015, Tandem native mass-spectrometry on antibody–drug conjugates and submillion Da antibody–antigen protein assemblies on an Orbitrap EMR equipped with a high-mass quadrupole mass selector, Anal. Chem., 87, 6095, 10.1021/acs.analchem.5b00788 Mo, 2012, Structural mass spectrometry in biologics discovery: advances and future trends, Drug Discov. Today, 17, 1323, 10.1016/j.drudis.2012.07.006 2013 Shen, 2012, Conjugation site modulates the in vivo stability and therapeutic activity of antibody–drug conjugates, Nat. Biotech., 30, 184, 10.1038/nbt.2108 Dorywalska, 2015, Effect of attachment site on stability of cleavable antibody drug conjugates, Bioconj. Chem., 26, 650, 10.1021/bc5005747 Dorywalska, 2015, Site-dependent degradation of a non-cleavable auristatin-based linker-payload in rodent plasma and its effect on ADC efficacy, PLoS ONE, 10, e0132282, 10.1371/journal.pone.0132282 Strop, 2013, Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates, Chem. Biol., 20, 161, 10.1016/j.chembiol.2013.01.010 Lyon, 2014, Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody–drug conjugates, Nat. Biotech., 32, 1059, 10.1038/nbt.2968 Tumey, 2014, Mild method for succinimide hydrolysis on ADCs: impact on ADC potency, stability, exposure, and efficacy, Bioconj. Chem., 25, 1871, 10.1021/bc500357n Fontaine, 2015, Long-term stabilization of maleimide–thiol conjugates, Bioconj. Chem., 26, 145, 10.1021/bc5005262 Saad, 2015, Bioanalytical approaches for characterizing catabolism of antibody–drug conjugates, Bioanalysis, 7, 1583, 10.4155/bio.15.87 Wei, 2013, High-resolution MS for structural characterization of protein therapeutics: advances and future directions, Bioanalysis, 5, 1299, 10.4155/bio.13.80 Hambly, 2005, Laser flash photolysis of hydrogen peroxide to oxidize protein solvent-accessible residues on the microsecond timescale, J. Am. Soc. Mass Spectrom., 16, 2057, 10.1016/j.jasms.2005.09.008 Jones, 2011, Fast photochemical oxidation of proteins for epitope mapping, Anal. Chem., 83, 7657, 10.1021/ac2007366 Yan, 2014, Fast photochemical oxidation of proteins (FPOP) maps the epitope of EGFR binding to adnectin, J. Am. Soc. Mass Spectrom., 25, 2084, 10.1007/s13361-014-0993-x Huang, 2014, Higher order structure characterization of protein therapeutics by hydrogen/deuterium exchange mass spectrometry, Anal. Bioanal. Chem., 406, 6541, 10.1007/s00216-014-7924-3 Wei, 2014, Hydrogen/deuterium exchange mass spectrometry for probing higher order structure of protein therapeutics: methodology and applications, Drug Discov. Today, 19, 95, 10.1016/j.drudis.2013.07.019 Zhang, 2014, Understanding the conformational impact of chemical modifications on monoclonal antibodies with diverse sequence variations using HDX-MS and structural modeling, Anal. Chem., 86, 3468, 10.1021/ac404130a Zhang, 2015, Effects of sucrose and benzyl alcohol on GCSF conformational dynamics revealed by hydrogen deuterium exchange mass spectrometry, J. Pharm. Sci., 104, 1592, 10.1002/jps.24384 Iacob, 2015, Hydrogen/deuterium exchange mass spectrometry applied to IL-23 interaction characteristics: potential impact for therapeutics, Expert Rev. Proteomics, 12, 159, 10.1586/14789450.2015.1018897 Pan, 2014, Conformation and dynamics of interchain cysteine-linked antibody–drug conjugates as revealed by hydrogen/deuterium exchange mass spectrometry, Anal. Chem., 86, 2657, 10.1021/ac404003q Pan, 2015, Antibody structural integrity of site-specific antibody–drug conjugates investigated by hydrogen/deuterium exchange mass spectrometry, Anal. Chem., 87, 5669, 10.1021/acs.analchem.5b00764 Myler, 2015, An integrated multiplatform bioanalytical strategy for antibody–drug conjugates: a novel case study, Bioanalysis, 7, 1569, 10.4155/bio.15.80 Kumar, 2015, Antibody–drug conjugates nonclinical support: from early to late nonclinical bioanalysis using ligand-binding assays, Bioanalysis, 7, 1605, 10.4155/bio.15.107 Liu, 2015, Quantitative bioanalysis of antibody-conjugated payload in monkey plasma using a hybrid immuno-capture LC–MS/MS approach: assay development, validation, and a case study, J. Chromatogr. B, 1002, 54, 10.1016/j.jchromb.2015.08.007 Kaur, 2013, Bioanalytical assay strategies for the development of antibody–drug conjugate biotherapeutics, Bioanalysis, 5, 201, 10.4155/bio.12.299